



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

08 April 2020

Imagion Biosystems receives A\$2.2 million in R&D tax incentives

- **Directors waive fees for current quarter**

MELBOURNE — Imagion Biosystems Limited (ASX: IBX) (the **Company**), a company dedicated to improving healthcare through the earlier detection of cancer, has received its 2019 R&D tax incentive claim of A\$2,197,028 from the Australian Tax Office (ATO).

In May 2019 the Company reported that it was eligible for an Advance/Overseas Finding from Innovation and Science Australia under the Research and Development Tax Incentive Program administered by the Australian Taxation Office and AusIndustry (a division of the Department of Industry, Innovation and Science), and in July 2019 received its first refund of \$2 million. Imagion Biosystems has now received a total of \$4.2 million in non-dilutive capital through the tax rebates in the last nine months.

In an effort to continue to conserve cash while the global COVID-19 pandemic plays out, the Directors have elected to waive their Director fees for the current quarter. Executive Chairman and CEO, Bob Proulx, does not receive director fees but will take an equivalent reduction from salary.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Buchan
imagionbiosystems@we-buchan.com
+61-3-9866-4722

Imagion Biosystems Limited

ACN 616 305 027

Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystem.com